Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVP-923 for Pseudobulbar Affect in ALS
NCT00021697Phase 3Completed
- Sponsor
- Avanir Pharmaceuticals
- Start
- Jan 2001
- Primary completion
- Apr 2002
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dextromethorphan + quinidine in pseudobulbar affect (PBA), sponsored by Avanir Pharmaceuticals. Started Jan 2001; status: completed.
02
Drugs
dextromethorphan + quinidine
03
Conditions
pseudobulbar affect (PBA)
Beyond the preview
Go deeper on NCT00021697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021697.